NFL Biosciences' NFL-101 Shows Promise as First-in-Class Smoking Cessation Treatment in Phase 2 Trial
核心洞察
NFL Biosciences (搜索) completed a Phase 2b study (CESTO 2) involving 318 patients across 9 French clinical centers, demonstrating efficacy comparable to existing smoking cessation (搜索) treatments.
The study highlighted NFL-101's significant reduction in craving and compulsion to smoke, which are key factors driving relapse during quit attempts.
NFL-101 operates through a unique mechanism involving immune system-brain communication, different from current nicotine receptor-targeting therapies.
NFL Biosciences (搜索) has announced positive results from its Phase 2b clinical trial CESTO 2, evaluating NFL-101, a first-in-class treatment for tobacco addiction (搜索). The multicenter, randomized, double-blind, placebo-controlled study involved 318 subjects across 9 clinical centers in France and was completed in 2024, with results published in July 2024 in Nicotine & Tobacco Research.
Clinical Trial Results Demonstrate Comparable Efficacy
The CESTO 2 study demonstrated efficacy comparable to that of other smoking cessation (搜索) treatments currently available. The primary endpoint was continuous abstinence for 4 weeks, with secondary endpoints including continuous abstinence for longer periods up to 12 months with a 12-month follow-up period.
The study notably highlighted a significant reduction in craving - the irresistible urge to smoke - and more specifically the compulsion to smoke, which are believed to be the driving factors behind NFL-101's effectiveness. Craving represents the main cause of relapse during quit attempts and is poorly alleviated by current smoking cessation (搜索) medications.
Unique Mechanism of Action Revealed
A mechanism-of-action study conducted in collaboration with CEA (搜索)'s Pharmacological Neuroimaging team provided insights into NFL-101's novel approach to smoking cessation (搜索). Using positron emission tomography (PET) imaging in mice, researchers monitored changes in brain function associated with tobacco dependence development.
The study demonstrated NFL-101's unique and disruptive mechanism of action, showing the treatment's ability to reduce craving through restoration of normal brain activity in the area of the brain associated with craving. The results suggest communication between the immune system and the central nervous system, representing a mode of action different from current smoking cessation (搜索) drugs which directly target nicotinic receptors (搜索).
Simplified Administration Protocol
NFL-101 is administered via two subcutaneous injections, with the first injection coinciding with the target quit date and the second injection administered one week later. This simplified dosing regimen facilitates adherence compared to daily oral medications currently available for smoking cessation (搜索).
Potential for Combination Therapy
Based on earlier Phase 2a results from the PRECESTO study, NFL-101 could be offered to any smoker wishing to increase their chances of success, whether or not they are using other smoking cessation (搜索) treatments simultaneously. The PRECESTO study demonstrated that NFL-101 reduces smoking satisfaction, with the reduction being greater than that observed with Champix®/Chantix®.
Safety Profile Established
Preclinical studies and Phase 1 (CESTO) and Phase 2a (PRECESTO) clinical studies have endorsed the safety of NFL-101. The Phase 1 study conducted on 24 smokers confirmed the safety of the product with the absence of side effects, while demonstrating a specific action on the immune system.
The development of NFL-101 was initiated following the observation of the efficacy of a tobacco leaf allergy desensitization treatment in smoking cessation (搜索). These observations open up new perspectives not only in smoking cessation, but also in the treatment of related co-addictions involving tobacco, cannabis, and alcohol.